Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | BECN1 | Q14457 | 2/20 | 0.37 |
| ▸ | NMT2 | O60551 | 1/20 | 0.37 |
| ▸ | NMT1 | P30419 | 1/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.37 |
| ▸ | RAMP3 | O60896 | 5/20 | 0.37 |
| ▸ | CALCR | P30988 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38655078 | 0.93 | MAPK8 (0.48) | MAPK8MAPK9MAPK10KEAP1NPBWR1 | |
| SCHEMBL30444128 | 0.90 | NMT1 (0.46) | NMT2NMT1 | |
| SCHEMBL29824782 | 0.90 | NMT1 (0.40) | MAPK8MAPK9MAPK10CPB2NMT2 | |
| SCHEMBL29496505 | 0.89 | PRCP (0.42) | MAPK8MAPK9MAPK10 | |
| SCHEMBL30844377 | 0.89 | RXFP1 (0.46) | MAPK8MAPK9MAPK10KEAP1BECN1 | |
| SCHEMBL29824904 | 0.88 | MEN1 (0.41) | MAPK8MAPK9MAPK10KEAP1RAMP3 | |
| SCHEMBL31195953 | 0.88 | MAPK8 (0.49) | MAPK8MAPK9MAPK10KEAP1RAMP3 | |
| SCHEMBL30440026 | 0.88 | MAPK8 (0.46) | MAPK8MAPK9MAPK10KEAP1RAMP3 | |
| SCHEMBL29980620 | 0.87 | PRCP (0.39) | MAPK8MAPK9MAPK10KEAP1 | |
| SCHEMBL9120793 | 0.87 | GHSR (0.41) | CPB2NMT2NMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570734-B2 | C-terminal anti-sclerostin antibody variants | AMGEN INC. (US) | 2026-03-10 | — | — | US | claimed |
| EP-3774879-B1 | C-TERMINAL ANTIBODY VARIANTS | AMGEN INC (US) | 2026-01-28 | — | — | EP | claimed |
| CN-119241705-A | C-terminal antibody variants | 安姆根有限公司 | 2025-01-03 | — | — | CN | claimed |
| US-20240352112-A1 | C-TERMINAL ANTIBODY VARIANTS | AMGEN INC. | 2024-10-24 | — | — | US | claimed |
| CN-112166120-B | C-terminal antibody variants | 安姆根有限公司 | 2024-09-10 | — | — | CN | claimed |
| US-11858983-B2 | C-terminal anti-sclerostin antibody variants | AMGEN INC. (US) | 2024-01-02 | — | — | US | claimed |
| US-20230015713-A1 | C-TERMINAL ANTIBODY VARIANTS | AMGEN INC. | 2023-01-19 | — | — | US | claimed |
| US-11466079-B2 | C-terminal antibody variants | AMGEN INC. (US) | 2022-10-11 | — | — | US | claimed |
| EP-4725548-A2 | C-TERMINAL ANTIBODY VARIANTS | AMGEN, INC. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12570734-B2 | C-terminal anti-sclerostin antibody variants | AMGEN INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-3774879-B1 | C-TERMINAL ANTIBODY VARIANTS | AMGEN INC (US) | 2026-01-28 | — | — | EP | disclosed |
| CN-119241705-A | C-terminal antibody variants | 安姆根有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20240352112-A1 | C-TERMINAL ANTIBODY VARIANTS | AMGEN INC. | 2024-10-24 | — | — | US | disclosed |
| CN-112166120-B | C-terminal antibody variants | 安姆根有限公司 | 2024-09-10 | — | — | CN | disclosed |
| US-11858983-B2 | C-terminal anti-sclerostin antibody variants | AMGEN INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230015713-A1 | C-TERMINAL ANTIBODY VARIANTS | AMGEN INC. | 2023-01-19 | — | — | US | disclosed |
| US-11466079-B2 | C-terminal antibody variants | AMGEN INC. (US) | 2022-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570734-B2 | C-terminal anti-sclerostin antibody variants | SOST, VSIG8, SET | MAPK8 1502/4885MAPK9 1804/4885MAPK10 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.